当前位置：
X-MOL 学术
›
Eur. Urol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108
European Urology ( IF 23.4 ) Pub Date : 2023-12-21 , DOI: 10.1016/j.eururo.2023.11.027 Miao Liu , Peng Chen , Tao Li
European Urology ( IF 23.4 ) Pub Date : 2023-12-21 , DOI: 10.1016/j.eururo.2023.11.027 Miao Liu , Peng Chen , Tao Li
Abstract not available
中文翻译：
回复：Fred Saad、Noel W. Clarke、Mototsugu Oya 等人。奥拉帕尼加阿比特龙与安慰剂加阿比特龙治疗转移性去势抵抗性前列腺癌 (PROpel)：随机、双盲、3 期试验的最终预设总体生存结果。柳叶刀 Oncol 2023;24:1094–108
摘要不可用
更新日期：2023-12-23
中文翻译：
回复：Fred Saad、Noel W. Clarke、Mototsugu Oya 等人。奥拉帕尼加阿比特龙与安慰剂加阿比特龙治疗转移性去势抵抗性前列腺癌 (PROpel)：随机、双盲、3 期试验的最终预设总体生存结果。柳叶刀 Oncol 2023;24:1094–108
摘要不可用
京公网安备 11010802027423号